Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF CLINICAL INFECTIOUS DISEASES   JULY 2016 , Volume 11 , Number 3; Page(s) 0 To 0.
 
Paper: 

EDITORIAL: THE DEBATE OVER TWO-DOSE OR THREE-DOSE HUMAN PAPILLOMAVIRUS VACCINE

 
 
Author(s):  MARDANI MASOUD*
 
* INFECTIOUS DISEASES AND TROPICAL MEDICINE RESEARCH CENTER, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, I.R. IRAN
 
Abstract: 

Cervical cancer is the fourth most common cancer in women around the world, and HPV types 16 and 18 are responsible for about 70% of cases (1). The HPV vaccine was initially developed in 2006 to be given in three doses over six months, but many countries are now moving to a twodose schedule for adolescents (2).

 
Keyword(s): HPV, VACCINE, CERVICAL CANCER CERVICAL CANCER
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

MARDANI, M. (2016). EDITORIAL: THE DEBATE OVER TWO-DOSE OR THREE-DOSE HUMAN PAPILLOMAVIRUS VACCINE. ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 11(3), 0-0. https://www.sid.ir/en/journal/ViewPaper.aspx?id=511191



Vancouver: Copy

MARDANI MASOUD. EDITORIAL: THE DEBATE OVER TWO-DOSE OR THREE-DOSE HUMAN PAPILLOMAVIRUS VACCINE. ARCHIVES OF CLINICAL INFECTIOUS DISEASES. 2016 [cited 2021September21];11(3):0-0. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=511191



IEEE: Copy

MARDANI, M., 2016. EDITORIAL: THE DEBATE OVER TWO-DOSE OR THREE-DOSE HUMAN PAPILLOMAVIRUS VACCINE. ARCHIVES OF CLINICAL INFECTIOUS DISEASES, [online] 11(3), pp.0-0. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=511191.



 
  pdf-File
Yearly Visit 229
 
 
Latest on Blog
Enter SID Blog